Brian Drummond is an associate in the firm’s Litigation Department and a member of its Intellectual Property Litigation practice. Mr. Drummond focuses his practice on patent matters, with a concentration on pharmaceuticals and biotechnology. He is an editor and contributor to the firm’s biosimilars blog, www.bigmoleculewatch.com. Mr. Drummond joined Goodwin in 2013.

Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. Drummond has participated in all phases of patent litigation, including pre-suit investigations, fact and expert discovery, several trials in federal courts, and appeals to the Federal Circuit. He has been involved in preparing petitions for inter partes review and defending clients in inter partes review proceedings. Mr. Drummond also counsels clients regarding litigation strategy and has experience in preparing patent opinions.

Representative matters include:

  • Shire Development LLC v. Actavis LaboratoriesFL, Inc. (D. Del.): Representing Actavis in a patent infringement litigation filed by Shire involving formulations of mixed salts of a single-entity amphetamine. The case is currently pending.
  • In re: Copaxone 775 Patent Litigation (D. Del.): Representing Teva in patent infringement litigation against multiple generic defendants involving patents directed to a process for manufacturing glatiramer acetate (Copaxone®).
  • Impax Labs., Inc. v. Actavis Labs. FL, Inc. (D.N.J): Representing Actavis in a patent infringement litigation filed by Impax involving formulations of levodopa and carbidopa and the treatment of Parkinson’s disease. The case is currently pending.
  • GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. (D. Del.): Representing Teva in patent infringement litigation filed by GSK concerning the drug Coreg® (carvedilol) used for the treatment of chronic heart failure, hypertension, and left ventricular dysfunction following myocardial infarction. After a jury trial, the U.S. District Court for the District of Delaware (Chief Judge Leonard P. Stark) granted Teva’s motion for judgment as a matter of law of no induced infringement.
  • In re: Copaxone 40mg Consolidated Cases (D. Del.): Representing Teva in a patent infringement litigation against five generic manufacturers involving patents directed to the treatment of multiple sclerosis with a novel dosing regimen for the drug glatiramer acetate. The case is on appeal to the U.S. Court of Appeals for the Federal Circuit.
  • Cadence Pharmaceuticals, Inc., et al. v. Fresenius Kabi USA, LLC (S.D. Cal.): Represented Fresenius in a patent infringement litigation filed by Cadence under the Hatch-Waxman Act in response to Fresenius’s filing of a 505(b)(2) application seeking approval to market a generic version of Cadence’s pain medication, OFIRMEV® (acetaminophen). The case settled favorably before trial.
  • Lifehealth, LLC v. Epocal, Inc. (D. W.Wisc.): Represented Epocal in a patent infringement litigation filed by Lifehealth concerning Epocal’s epoc™ blood gas analysis system. The case settled favorably.
  • Idexx Labs., Inc. v. Charles River Labs., Inc. (D. Del.): Represented Charles River Labs in a patent infringement litigation involving dried blood spot technology. The case settled favorably.
  • In re Bendamustine Consolidated Litigation (D. Del.): Representing Cephalon, Inc. in patent litigation against 18 defendants involving Cephalon’s branded cancer drug, Treanda®, which is indicated for the treatment of certain lymphomas. The U.S. District Court for the District of Delaware (Judge Gregory M. Sleet) issued a final decision in favor of Cephalon, upholding the validity and finding infringement of all patents-in-suit following a six-day bench trial. The case is now on appeal to the U.S. Court of Appeals for the Federal Circuit.
  • Mylan Pharmaceuticals, Inc. v. Yeda Research and Development (PTAB): Representing patent owner Yeda Research and Development in an inter partes review proceeding involving patents directed to the treatment of multiple sclerosis with a novel dosing regimen for the drug glatiramer acetate. The case is on appeal to the U.S. Court of Appeals for the Federal Circuit.
  • In re: Zoledronic Acid Patent Litigation (D.N.J.): Represented Fresenius Kabi, Gland Pharma Ltd. and USV North America as generic defendants in patent litigation concerning the bone disorder treatment Zometa® (zoledronic acid) brought in the U.S. District Court, District of New Jersey. Favorable settlements were obtained.
  • Nautilus Neurosciences, Inc. v. Wockhardt  USA LLC (D.N.J.): Represented defendant Wockhardt in patent infringement action relating to diclofenac potassium. The case settled favorably.
Professional Activities

Mr. Drummond is a member of the Boston Bar Association.

Mr. Drummond’s pro bono work includes helping unaccompanied refugee minors become U.S. legal residents through Immigration proceedings. Mr. Drummond has also represented indigent defendants pro bono in federal criminal cases.

Professional Experience

Prior to joining Goodwin, Mr. Drummond was an associate in the Orange County office of Knobbe Martens Olson & Bear.

Recognition

While attending law school, Mr. Drummond was Symposium Editor for the Boston College Environmental Law Review.

In The News

MELDUNGEN

ACTUALITÉS

在新闻中

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2011
Boston College Law School
B.S., Chemical Engineering, 2008
Case Western Reserve University
Get In Touch
German Translation
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师